Skip to main content
NASDAQ:XFOR

X4 Pharmaceuticals Competitors

$7.66
+0.21 (+2.82 %)
(As of 05/14/2021 12:31 PM ET)
Add
Compare
Today's Range
$7.19
$7.82
50-Day Range
$7.91
$9.56
52-Week Range
$5.38
$11.11
Volume2,666 shs
Average Volume113,695 shs
Market Capitalization$133.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53

Competitors

X4 Pharmaceuticals (NASDAQ:XFOR) Vs. PSTX, CGEN, SLDB, OYST, APTO, and GRTS

Should you be buying XFOR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to X4 Pharmaceuticals, including Poseida Therapeutics (PSTX), Compugen (CGEN), Solid Biosciences (SLDB), Oyster Point Pharma (OYST), Aptose Biosciences (APTO), and Gritstone bio (GRTS).

Poseida Therapeutics (NASDAQ:PSTX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Profitability

This table compares Poseida Therapeutics and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Poseida TherapeuticsN/AN/AN/A
X4 PharmaceuticalsN/A-47.06%-35.89%

Valuation and Earnings

This table compares Poseida Therapeutics and X4 Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poseida TherapeuticsN/AN/AN/A($6.86)-1.26
X4 PharmaceuticalsN/AN/A$-52,810,000.00($4.63)-1.65

X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Poseida Therapeutics and X4 Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Poseida Therapeutics00303.00
X4 Pharmaceuticals00403.00

Poseida Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 198.69%. X4 Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 130.18%. Given Poseida Therapeutics' higher possible upside, research analysts plainly believe Poseida Therapeutics is more favorable than X4 Pharmaceuticals.

Insider and Institutional Ownership

41.1% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are owned by institutional investors. 19.0% of Poseida Therapeutics shares are owned by company insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Poseida Therapeutics beats X4 Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Compugen and X4 Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$17.80 million31.06$-27,340,000.00($0.43)-18.79
X4 PharmaceuticalsN/AN/A$-52,810,000.00($4.63)-1.65

Compugen has higher revenue and earnings than X4 Pharmaceuticals. Compugen is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Compugen has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Compugen and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CompugenN/A-26.98%-23.28%
X4 PharmaceuticalsN/A-47.06%-35.89%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Compugen and X4 Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Compugen00403.00
X4 Pharmaceuticals00403.00

Compugen presently has a consensus price target of $18.25, indicating a potential upside of 125.03%. X4 Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 130.18%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Compugen.

Summary

Compugen beats X4 Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Earnings & Valuation

This table compares Solid Biosciences and X4 Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-1.20
X4 PharmaceuticalsN/AN/A$-52,810,000.00($4.63)-1.65

X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

42.7% of Solid Biosciences shares are owned by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are owned by institutional investors. 31.2% of Solid Biosciences shares are owned by insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Solid Biosciences and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
X4 PharmaceuticalsN/A-47.06%-35.89%

Risk and Volatility

Solid Biosciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Solid Biosciences and X4 Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences01402.80
X4 Pharmaceuticals00403.00

Solid Biosciences currently has a consensus price target of $12.40, indicating a potential upside of 257.35%. X4 Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 130.18%. Given Solid Biosciences' higher possible upside, research analysts clearly believe Solid Biosciences is more favorable than X4 Pharmaceuticals.

Oyster Point Pharma (NASDAQ:OYST) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Profitability

This table compares Oyster Point Pharma and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oyster Point PharmaN/A-39.61%-37.68%
X4 PharmaceuticalsN/A-47.06%-35.89%

Insider & Institutional Ownership

70.2% of Oyster Point Pharma shares are held by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are held by institutional investors. 36.9% of Oyster Point Pharma shares are held by company insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Oyster Point Pharma has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares Oyster Point Pharma and X4 Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-1.64
X4 PharmaceuticalsN/AN/A$-52,810,000.00($4.63)-1.65

X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Oyster Point Pharma and X4 Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oyster Point Pharma00103.00
X4 Pharmaceuticals00403.00

X4 Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 130.18%. Given X4 Pharmaceuticals' higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Oyster Point Pharma.

Summary

X4 Pharmaceuticals beats Oyster Point Pharma on 6 of the 10 factors compared between the two stocks.

Aptose Biosciences (NASDAQ:APTO) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Institutional and Insider Ownership

52.2% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are owned by institutional investors. 6.3% of Aptose Biosciences shares are owned by insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Aptose Biosciences and X4 Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-9.33
X4 PharmaceuticalsN/AN/A$-52,810,000.00($4.63)-1.65

Aptose Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aptose Biosciences and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/A-49.53%-46.65%
X4 PharmaceuticalsN/A-47.06%-35.89%

Analyst Recommendations

This is a breakdown of current ratings for Aptose Biosciences and X4 Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00803.00
X4 Pharmaceuticals00403.00

Aptose Biosciences currently has a consensus target price of $11.6250, indicating a potential upside of 142.69%. X4 Pharmaceuticals has a consensus target price of $18.00, indicating a potential upside of 130.18%. Given Aptose Biosciences' higher possible upside, equities analysts clearly believe Aptose Biosciences is more favorable than X4 Pharmaceuticals.

Volatility and Risk

Aptose Biosciences has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Summary

Aptose Biosciences beats X4 Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Gritstone bio (NASDAQ:GRTS) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Institutional & Insider Ownership

59.0% of Gritstone bio shares are owned by institutional investors. Comparatively, 67.8% of X4 Pharmaceuticals shares are owned by institutional investors. 38.0% of Gritstone bio shares are owned by company insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Gritstone bio has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings & Valuation

This table compares Gritstone bio and X4 Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone bio$4.36 million98.96$-94,430,000.00($2.81)-3.12
X4 PharmaceuticalsN/AN/A$-52,810,000.00($4.63)-1.65

X4 Pharmaceuticals has lower revenue, but higher earnings than Gritstone bio. Gritstone bio is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gritstone bio and X4 Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gritstone bio-2,962.52%-101.31%-68.78%
X4 PharmaceuticalsN/A-47.06%-35.89%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gritstone bio and X4 Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gritstone bio10202.33
X4 Pharmaceuticals00403.00

Gritstone bio currently has a consensus target price of $22.3333, indicating a potential upside of 157.59%. X4 Pharmaceuticals has a consensus target price of $18.00, indicating a potential upside of 130.18%. Given Gritstone bio's higher probable upside, equities research analysts plainly believe Gritstone bio is more favorable than X4 Pharmaceuticals.

Summary

X4 Pharmaceuticals beats Gritstone bio on 8 of the 13 factors compared between the two stocks.


X4 Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.6$8.62+3.6%$516.33 millionN/A-1.26Earnings Announcement
Analyst Upgrade
Compugen logo
CGEN
Compugen
1.4$8.08+8.3%$506.99 million$17.80 million-21.84Earnings Announcement
Unusual Options Activity
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$3.49+27.2%$489.72 millionN/A-1.69Gap Down
Oyster Point Pharma logo
OYST
Oyster Point Pharma
0.9$16.33+0.5%$422.14 millionN/A-4.71
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.85+4.7%$410.81 millionN/A-7.58
Gritstone bio logo
GRTS
Gritstone bio
1.6$8.77+7.1%$400.96 million$4.36 million-3.07Analyst Downgrade
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$7.57+4.5%$370.23 million$147.87 million-2.51
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$17.87+6.8%$367.25 millionN/A0.00Gap Up
AVROBIO logo
AVRO
AVROBIO
1.9$9.60+8.4%$367.12 millionN/A-2.91Earnings Announcement
Analyst Report
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.4$8.27+1.8%$357.39 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$3.67+1.4%$354.53 million$250,000.00-2.89Analyst Downgrade
Opthea logo
OPT
Opthea
1.5$8.03+3.5%$348.96 millionN/A0.00Gap Up
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.3$2.06+5.8%$336.80 million$8.15 million-1.65Upcoming Earnings
Gap Up
Surface Oncology logo
SURF
Surface Oncology
1.4$7.68+4.2%$319.64 million$15.36 million-11.64
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.63+1.6%$318.82 million$250,000.00-3.08Earnings Announcement
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.10+0.8%$316.69 million$2.91 million-2.13Analyst Report
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.00+5.7%$315.62 millionN/A0.00Earnings Announcement
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.7$9.44+7.3%$313.73 millionN/A0.00Analyst Report
News Coverage
Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$3.95+3.0%$312.01 million$96.12 million-11.62Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.18+1.8%$272.63 millionN/A-3.37Analyst Report
Analyst Revision
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$9.42+6.8%$218.87 millionN/A-6.88
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.48+4.1%$198.51 million$4.13 million-3.29Earnings Announcement
Analyst Report
News Coverage
Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.77+8.5%$196.47 million$29.35 million-2.06Earnings Announcement
Genfit logo
GNFT
Genfit
1.3$4.11+1.5%$188.14 million$45.88 million-2.09
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.51+4.9%$161.85 million$104.39 million-2.75Earnings Announcement
Analyst Report
Analyst Revision
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.46+4.0%$161.22 millionN/A-7.88Earnings Announcement
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.89+5.7%$156.90 million$2.45 million-1.83Upcoming Earnings
News Coverage
Gap Up
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.61+4.7%$152.59 millionN/A-4.62Earnings Announcement
Analyst Revision
News Coverage
PolarityTE logo
PTE
PolarityTE
1.5$0.99+24.8%$150.00 million$5.65 million-0.60Earnings Announcement
Unusual Options Activity
News Coverage
Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.83+8.3%$142.47 millionN/A-3.02Earnings Announcement
Analyst Revision
News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.51+7.5%$140.75 millionN/A-1.66
INmune Bio logo
INMB
INmune Bio
1.5$10.32+10.0%$138.73 millionN/A-10.64Analyst Downgrade
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.27+1.6%$133.43 millionN/A0.00Earnings Announcement
Gap Up
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.00+2.0%$129.76 million$2.33 million0.00News Coverage
Gap Up
Axcella Health logo
AXLA
Axcella Health
1.6$3.41+2.3%$125.61 millionN/A-1.59Analyst Revision
News Coverage
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.34+2.9%$121.45 million$32.12 million-71.85
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.40+5.3%$116.95 millionN/A-3.24
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.84+7.8%$112.36 million$20,000.000.00Upcoming Earnings
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.21+6.8%$112.14 millionN/A-1.52Analyst Revision
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.7$11.00+1.0%$111.36 millionN/A0.00Insider Buying
Dyadic International logo
DYAI
Dyadic International
1.3$3.88+1.0%$105.81 million$1.68 million-11.41Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.01+0.5%$97.55 million$20.92 million-1.16Earnings Announcement
News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.05+4.1%$97.47 millionN/A0.00Analyst Upgrade
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.72+5.9%$96.07 million$23.05 million-1.65Analyst Downgrade
Analyst Revision
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.00+3.5%$92.30 million$140,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.04+3.8%$90.07 million$3 million-1.94
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$4.60+14.1%$79.56 million$10,000.000.00Upcoming Earnings
Gap Up
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.12+1.8%$65.68 millionN/A-0.89Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.63+0.3%$57.96 million$420,000.00-1.36Earnings Announcement
News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.81+4.8%$56.89 million$7.92 million-0.34Earnings Announcement
News Coverage
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.